Obesity market competition is expanding beyond weight-loss efficacy as retatrutide raises clinical expectations, oral GLP-1 programs advance, Asia-Pacific pricing strategies evolve, and specialized treatments create new opportunities for differentiation and commercialization.
Coverage Period: October 5 – November 6, 2026
Introduction
The defining story of this reporting period is the emergence of multiple competitive pathways in obesity therapeutics, as stronger clinical efficacy, flexible dosing, regional pricing, and specialized treatment approaches begin to challenge the industry’s reliance on weight loss alone as the primary measure of differentiation.
Eli Lilly’s new retatrutide data raised expectations for triple-receptor agonists, while Viking Therapeutics advanced oral VK2735 into Phase 3. At the same time, South Korea’s launch of a lower-priced domestic treatment and Pfizer’s commercialization activities in China demonstrated how access and local market dynamics are becoming more important. Growing interest in muscle preservation and rare obesity disorders adds another dimension to the competitive landscape.
Companies covered: Eli Lilly, Viking Therapeutics, Pfizer, Hanmi Pharmaceutical
Clinical areas covered: Obesity, rare obesity indications, obesity management with a focus on lean mass preservation
Executive Summary
- Triple-receptor agonists are raising the efficacy benchmark in obesity and diabetes. Retatrutide’s Phase 3 head-to-head results against semaglutide reinforce the clinical potential of targeting GLP-1, GIP, and glucagon receptors. Stronger weight reduction and glycemic control could influence future treatment positioning, although tolerability and long-term outcomes remain important considerations.
- Oral obesity therapies and flexible dosing are becoming key areas of differentiation. Viking’s Phase 3 oral VK2735 program, alongside emerging extended-interval injectable and maintenance approaches, reflects growing interest in accommodating different patient preferences and long-term treatment needs. Convenience could become an important competitive advantage, but its impact on adherence remains uncertain.
- Asia-Pacific is becoming a more influential obesity innovation and commercialization market. China’s expanding development pipeline, South Korea’s launch of domestically developed efpeglenatide, and Pfizer’s China-focused ecnoglutide strategy highlight competition extending beyond clinical efficacy to pricing, distribution, reimbursement, and regional partnerships.
- Obesity drug development is expanding toward differentiated metabolic and specialized indications. Interest in lean-mass preservation, non-incretin mechanisms, and rare obesity disorders indicates opportunities beyond conventional weight-management therapies. These approaches could support more targeted portfolios, although clinical validation and commercial scalability remain unresolved.
Watch the video summary
Strategic Perspective on Four Emerging Shifts Reshaping the Obesity Market
Triple-Receptor Agonists Raise Efficacy Expectations: Eli Lilly’s Retatrutide and Hanmi’s Zantrutide
The latest retatrutide results strengthen the clinical case for multi-receptor agonists as a potential next stage in obesity treatment.
In the Phase 3 TRANSCEND-T2D-2 trial, retatrutide achieved weight reductions of 19.5% and 20.9% at the two evaluated doses, compared with 9.4% for semaglutide 2 mg. HbA1c reductions reached 2.2 percentage points with retatrutide versus 1.8 points with semaglutide.
The findings provide direct comparative evidence of greater weight reduction and glycemic improvement in adults with type 2 diabetes. However, adverse-event discontinuations were higher in the retatrutide groups, highlighting the trade-offs that may accompany stronger efficacy.
Other developers are pursuing similar biology. Hanmi Pharmaceutical’s zantrutide, a GLP-1/GIP/glucagon triple agonist in Phase 2, is being developed with the additional objective of limiting muscle loss during weight reduction.
Market implications: Higher efficacy expectations could increase competitive pressure on existing therapies and late-stage candidates. Developers may need to demonstrate differentiated benefits in tolerability, metabolic outcomes, body composition, or treatment convenience rather than relying solely on weight-loss percentages.
Key uncertainty: Retatrutide’s comparative efficacy is encouraging, but its long-term safety, treatment persistence, and eventual positioning remain to be established. Whether other triple agonists can reproduce these benefits in larger trials is also unresolved.
Oral GLP-1 Therapies and Flexible Dosing Could Expand Treatment Options: Viking Advances VK2735
Oral formulations and alternative dosing schedules are becoming more important as obesity treatment evolves toward long-term disease management.
Viking Therapeutics’ initiation of the Phase 3 SUNRISE program for once-daily oral VK2735 marks an important development for oral dual GLP-1/GIP agonists. The program includes separate studies in adults with obesity and those with overweight or obesity and type 2 diabetes.
Viking is also evaluating maintenance strategies involving oral treatment and less frequent injections, alongside its weekly injectable Phase 3 program.
The direction is reinforced by Asia-Pacific developers advancing oral GLP-1 candidates and investigating extended-interval injections, including monthly dosing.
These approaches address a practical challenge in obesity care: patients may require different treatment formats during initiation, active weight reduction, and long-term maintenance.
Market implications: Formulation flexibility could broaden treatment choice and support portfolio-based competition. Companies offering both injectable and oral options may be better positioned to address differences in patient preferences, clinical needs, and healthcare access. Longer dosing intervals could also provide differentiation in an increasingly crowded market.
Key uncertainty: Greater convenience does not automatically improve adherence or persistence. Comparative efficacy, tolerability, cost, and real-world treatment continuation will determine the commercial value of these approaches.
Asia-Pacific Pricing and Access Shape Obesity Market Competition: Hanmi’s Efpeglenatide and Pfizer’s Ecnoglutide
Asia-Pacific is becoming an increasingly important source of obesity drug innovation while developing distinct commercial models.
The supplied regional pipeline assessment identifies 30 Asia-Pacific-originated obesity candidates in registered human trials, including 21 from China and six from South Korea. Several have progressed into late-stage development, regulatory review, or domestic commercialization.
South Korea’s launch of Hanmi Pharmaceutical’s efpeglenatide illustrates how local manufacturers may challenge established products through pricing. Its initial four-week supply price of approximately KRW 129,800 was substantially below the cited starting-dose price of Mounjaro, creating a potential affordability advantage despite differences in clinical efficacy.
In China, Pfizer’s commercialization of ecnoglutide through its partnership with Sciwind Biosciences highlights another approach. Pfizer is targeting different patient segments and commercial channels while pursuing reimbursement access to strengthen its position against established competitors.
These developments show that competitive success may differ considerably across markets, depending on affordability, reimbursement, physician familiarity, and supply capabilities.
Market implications: Regional innovation could create new licensing opportunities and increase pricing pressure on multinational companies. Local manufacturing and commercialization partnerships may become important advantages, particularly in markets where out-of-pocket spending influences treatment adoption.
Key uncertainty: Lower prices and regional market entry do not guarantee sustained uptake. Early prescribing trends, reimbursement decisions, long-term safety evidence, and competition from established therapies will determine whether domestic products can secure meaningful market share.
Muscle Preservation and Rare Obesity Indications Expand Differentiation Opportunities: Hanmi and Rhythm Pharmaceuticals
Obesity drug development is beginning to address limitations and patient populations that conventional incretin therapies may not fully serve.
Muscle preservation is one emerging priority. Hanmi’s development programs include approaches intended to limit lean-mass loss, while other early-stage mechanisms focus on body composition rather than weight reduction alone.
The commercial rationale is that treatment quality may eventually be evaluated through changes in fat mass, lean tissue, metabolic health, and physical function alongside total weight loss.
Interest in specialized obesity indications provides a second source of differentiation.
Reports that AstraZeneca made a non-binding acquisition proposal of approximately $10 billion for Rhythm Pharmaceuticals illustrate the potential strategic value of established rare obesity franchises. Rhythm’s therapies address specific genetic and acquired forms of obesity, including acquired hypothalamic obesity.
Unlike mass-market incretin competition, these indications offer opportunities to develop treatments around distinct disease biology and clearly defined patient populations.
Market implications: Specialized mechanisms and targeted indications could create opportunities for companies seeking differentiated obesity portfolios without directly competing on maximum weight loss. They may also support partnerships between metabolic disease developers and companies with established rare-disease capabilities.
Key uncertainty: Evidence supporting lean-mass preservation remains early, and improvements in body composition must translate into meaningful clinical benefits. The commercial potential of specialized obesity treatments also depends on eligible patient populations, reimbursement, and sustained treatment outcomes.
What We Are Watching Next in Obesity Drug Development and Market Competition
- Triple-agonist clinical differentiation: Additional retatrutide results and upcoming zantrutide data could clarify the relationship between greater efficacy, tolerability, and body-composition outcomes.
- Oral and extended-interval obesity treatments: Progress in Viking’s SUNRISE program, oral ecnoglutide, and longer-acting injectable candidates will help assess the clinical and commercial value of flexible dosing.
- China’s next regulatory decisions: Reviews involving HRS9531, olatorepatide, and BGM0504 could expand domestic competition and influence future international licensing strategies.
- Regional commercialization and reimbursement: Early efpeglenatide prescribing trends in South Korea and ecnoglutide reimbursement developments in China will provide evidence of how pricing and market access affect adoption.
- Specialized obesity portfolio development: Clinical progress in muscle-preserving mechanisms and further business development involving rare obesity assets could indicate where companies see opportunities beyond conventional incretin therapies.
Key Takeaway: Clinical and Commercial Differentiation Reshape Obesity Market Competition
The obesity therapeutics market is moving from a predominantly efficacy-driven competitive model toward one shaped by multiple forms of clinical and commercial differentiation.
Triple-receptor agonists are raising expectations for weight reduction, while oral formulations and flexible dosing could expand treatment choice. At the same time, Asia-Pacific commercialization strategies demonstrate the growing importance of pricing and market access, and specialized mechanisms offer opportunities beyond mainstream obesity treatment.
For biopharma companies, the emerging challenge is not simply to develop a more effective weight-loss therapy. It is to establish a treatment profile and commercial strategy that can remain competitive across different patient needs, healthcare systems, and stages of long-term obesity management.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com